{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:33:35Z","timestamp":1789238015251,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T00:00:00Z","timestamp":1275523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T00:00:00Z","timestamp":1275523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/leu.2010.117","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T09:44:20Z","timestamp":1275558260000},"page":"1476-1486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNF\u03b1\/NF-\u03baB signaling axis"],"prefix":"10.1038","volume":"24","author":[{"given":"Z","family":"Zak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Gelebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,3]]},"reference":[{"key":"BFleu2010117_CR1","first-page":"649","volume":"20","author":"B Desvergne","year":"1999","unstructured":"Desvergne B, Wahli W . Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649\u2013688.","journal-title":"Endocr Rev"},{"key":"BFleu2010117_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/35013000","volume":"405","author":"S Kersten","year":"2000","unstructured":"Kersten S, Desvergne B, Wahli W . Roles of PPARs in health and disease. Nature 2000; 405: 421\u2013424.","journal-title":"Nature"},{"key":"BFleu2010117_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1126\/science.3283939","volume":"240","author":"RM Evans","year":"1988","unstructured":"Evans RM . The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889\u2013895.","journal-title":"Science"},{"key":"BFleu2010117_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0303-7207(94)90294-1","volume":"100","author":"S Green","year":"1994","unstructured":"Green S, Wahli W . Peroxisome proliferator-activated receptors: finding the orphan a home. Mol Cell Endocrinol 1994; 100: 149\u2013153.","journal-title":"Mol Cell Endocrinol"},{"key":"BFleu2010117_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s000110050622","volume":"49","author":"G Chinetti","year":"2000","unstructured":"Chinetti G, Fruchart JC, Staels B . Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497\u2013505.","journal-title":"Inflamm Res"},{"key":"BFleu2010117_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/31701","volume":"393","author":"B Staels","year":"1998","unstructured":"Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790\u2013793.","journal-title":"Nature"},{"key":"BFleu2010117_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1677\/joe.0.1690453","volume":"169","author":"P Delerive","year":"2001","unstructured":"Delerive P, Fruchart JC, Staels B . Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453\u2013459.","journal-title":"J Endocrinol"},{"key":"BFleu2010117_CR8","doi-asserted-by":"publisher","first-page":"32833","DOI":"10.1074\/jbc.273.49.32833","volume":"273","author":"ME Poynter","year":"1998","unstructured":"Poynter ME, Daynes RA . Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833\u201332841.","journal-title":"J Biol Chem"},{"key":"BFleu2010117_CR9","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","volume":"274","author":"P Delerive","year":"1999","unstructured":"Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048\u201332054.","journal-title":"J Biol Chem"},{"key":"BFleu2010117_CR10","first-page":"345","volume":"36","author":"A Madej","year":"1998","unstructured":"Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998; 36: 345\u2013349.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"BFleu2010117_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/283397a0","volume":"283","author":"JK Reddy","year":"1980","unstructured":"Reddy JK, Azarnoff DL, Hignite CE . Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980; 283: 397\u2013398.","journal-title":"Nature"},{"key":"BFleu2010117_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0303-7207(02)00098-9","volume":"193","author":"FJ Gonzalez","year":"2002","unstructured":"Gonzalez FJ . The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis. Mol Cell Endocrinol 2002; 193: 71\u201379.","journal-title":"Mol Cell Endocrinol"},{"key":"BFleu2010117_CR13","first-page":"129","volume":"85","author":"M Childs","year":"1992","unstructured":"Childs M, Girardot G . [Evaluation of acquired data on long-term risk of hypolipidemic treatments]. Arch Mal Coeur Vaiss 1992; 85(Spec No. 2): 129\u2013133.","journal-title":"Arch Mal Coeur Vaiss"},{"key":"BFleu2010117_CR14","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1158\/0008-5472.CAN-04-0322","volume":"64","author":"C Cheung","year":"2004","unstructured":"Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C et al. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res 2004; 64: 3849\u20133854.","journal-title":"Cancer Res"},{"key":"BFleu2010117_CR15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1124\/jpet.103.049098","volume":"305","author":"S Laurora","year":"2003","unstructured":"Laurora S, Pizzimenti S, Briatore F, Fraioli A, Maggio M, Reffo P et al. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther 2003; 305: 932\u2013942.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu2010117_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.cdd.4400551","volume":"6","author":"R Scatena","year":"1999","unstructured":"Scatena R, Nocca G, Sole PD, Rumi C, Puggioni P, Remiddi F et al. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 1999; 6: 781\u2013787.","journal-title":"Cell Death Differ"},{"key":"BFleu2010117_CR17","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1182\/blood-2005-05-2103","volume":"107","author":"H Liu","year":"2006","unstructured":"Liu H, Zang C, Fenner MH, Liu D, Possinger K, Koeffler HP et al. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha\/gamma ligand TZD18. Blood 2006; 107: 3683\u20133692.","journal-title":"Blood"},{"key":"BFleu2010117_CR18","first-page":"833","volume":"18","author":"T Shigeto","year":"2007","unstructured":"Shigeto T, Yokoyama Y, Xin B, Mizunuma H . Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol Rep 2007; 18: 833\u2013840.","journal-title":"Oncol Rep"},{"key":"BFleu2010117_CR19","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/ijc.23004","volume":"121","author":"G Muzio","year":"2007","unstructured":"Muzio G, Maggiora M, Oraldi M, Trombetta A, Canuto RA . PPARalpha and PP2A are involved in the proapoptotic effect of conjugated linoleic acid on human hepatoma cell line SK-HEP-1. Int J Cancer 2007; 121: 2395\u20132401.","journal-title":"Int J Cancer"},{"key":"BFleu2010117_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1073\/pnas.0711281105","volume":"105","author":"D Panigrahy","year":"2008","unstructured":"Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105: 985\u2013990.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2010117_CR21","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"S Swerdlow","year":"2001","unstructured":"Swerdlow S, Berger F, Isaacson P, Muller-Hermelink H . Mantle cell lymphoma. In: Harris NL, Jaffe ES, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001."},{"key":"BFleu2010117_CR22","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc2230","volume":"7","author":"P Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E . Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750\u2013762.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2010117_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MOH.0b013e328302c9c5","volume":"15","author":"MR Smith","year":"2008","unstructured":"Smith MR . Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol 2008; 15: 415\u2013421.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2010117_CR24","first-page":"8226","volume":"63","author":"N Martinez","year":"2003","unstructured":"Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226\u20138232.","journal-title":"Cancer Res"},{"key":"BFleu2010117_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ . Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88\u201395.","journal-title":"J Immunol"},{"key":"BFleu2010117_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bcp.2005.04.043","volume":"70","author":"S Shishodia","year":"2005","unstructured":"Shishodia S, Amin HM, Lai R, Aggarwal BB . Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1\/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 70: 700\u2013713.","journal-title":"Biochem Pharmacol"},{"key":"BFleu2010117_CR27","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1182\/blood-2005-10-4042","volume":"107","author":"L Fu","year":"2006","unstructured":"Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ . Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006; 107: 4540\u20134548.","journal-title":"Blood"},{"key":"BFleu2010117_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1535-7163.MCT-07-0302","volume":"7","author":"CA Tucker","year":"2008","unstructured":"Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM et al. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol Cancer Ther 2008; 7: 749\u2013758.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2010117_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","volume":"130","author":"EG Rizzatti","year":"2005","unstructured":"Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005; 130: 516\u2013526.","journal-title":"Br J Haematol"},{"key":"BFleu2010117_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1080\/10428190801910912","volume":"49","author":"EG Rizzatti","year":"2008","unstructured":"Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M et al. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma 2008; 49: 798\u2013808.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2010117_CR31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","volume":"114","author":"M Ghielmini","year":"2009","unstructured":"Ghielmini M, Zucca E . How I treat mantle cell lymphoma. Blood 2009; 114: 1469\u20131476.","journal-title":"Blood"},{"key":"BFleu2010117_CR32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","volume":"127","author":"HM Amin","year":"2003","unstructured":"Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O\u2019Connor SL et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003; 127: 424\u2013431.","journal-title":"Arch Pathol Lab Med"},{"key":"BFleu2010117_CR33","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/leu.2009.100","volume":"23","author":"P Gelebart","year":"2009","unstructured":"Gelebart P, Zak Z, Anand M, Dien-Bard J, Amin HM, Lai R . Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 2009; 23: 1836\u20131846.","journal-title":"Leukemia"},{"key":"BFleu2010117_CR34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/415813a","volume":"415","author":"HE Xu","year":"2002","unstructured":"Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002; 415: 813\u2013817.","journal-title":"Nature"},{"key":"BFleu2010117_CR35","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1038\/leu.2008.213","volume":"22","author":"M Klier","year":"2008","unstructured":"Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22: 2097\u20132105.","journal-title":"Leukemia"},{"key":"BFleu2010117_CR36","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1161\/CIRCRESAHA.108.186205","volume":"103","author":"F Gizard","year":"2008","unstructured":"Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL et al. The PPARalpha\/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res 2008; 103: 1155\u20131163.","journal-title":"Circ Res"},{"key":"BFleu2010117_CR37","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1159\/000116885","volume":"28","author":"X Zhao","year":"2008","unstructured":"Zhao X, Li LY . PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008; 28: 598\u2013606.","journal-title":"Am J Nephrol"},{"key":"BFleu2010117_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1476-4598-5-13","volume":"5","author":"SA Saidi","year":"2006","unstructured":"Saidi SA, Holland CM, Charnock-Jones DS, Smith SK . In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006; 5: 13.","journal-title":"Mol Cancer"},{"key":"BFleu2010117_CR39","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1161\/01.CIR.99.24.3125","volume":"99","author":"N Marx","year":"1999","unstructured":"Marx N, Sukhova GK, Collins T, Libby P, Plutzky J . PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125\u20133131.","journal-title":"Circulation"},{"key":"BFleu2010117_CR40","first-page":"323","volume":"23","author":"H Okamoto","year":"2005","unstructured":"Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N . Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 323\u2013330.","journal-title":"Clin Exp Rheumatol"},{"key":"BFleu2010117_CR41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.jacc.2003.11.043","volume":"43","author":"T Ogata","year":"2004","unstructured":"Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I . Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481\u20131488.","journal-title":"J Am Coll Cardiol"},{"key":"BFleu2010117_CR42","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0092-8674(93)90508-N","volume":"74","author":"LH Boise","year":"1993","unstructured":"Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597\u2013608.","journal-title":"Cell"},{"key":"BFleu2010117_CR43","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1345\/aph.18432","volume":"33","author":"DR Guay","year":"1999","unstructured":"Guay DR . Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 1999; 33: 1083\u20131103.","journal-title":"Ann Pharmacother"},{"issue":"Suppl 3","key":"BFleu2010117_CR44","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.3132\/dvdr.2007.053","volume":"4","author":"A Zambon","year":"2007","unstructured":"Zambon A, Cusi K . The role of fenofibrate in clinical practice. Diab Vasc Dis Res 2007; 4 (Suppl 3): S15\u2013S20.","journal-title":"Diab Vasc Dis Res"},{"issue":"5 Suppl 1","key":"BFleu2010117_CR45","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jaad.2007.07.012","volume":"58","author":"M Steinhoff","year":"2008","unstructured":"Steinhoff M, Beyer M, Roewert-Huber J, Lukowsky A, Assaf C, Sterry W . Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. J Am Acad Dermatol 2008; 58 (5 Suppl 1): S88\u2013S91.","journal-title":"J Am Acad Dermatol"},{"key":"BFleu2010117_CR46","first-page":"184","volume":"26","author":"M Krempf","year":"2000","unstructured":"Krempf M, Rohmer V, Farnier M, Issa-Sayegh M, Corda C, Sirugue I et al. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200\u2013400\u2009mg daily with placebo in patients with hypercholesterolemia. Diabetes Metab 2000; 26: 184\u2013191.","journal-title":"Diabetes Metab"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2010117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010117","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:34:13Z","timestamp":1648733653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,3]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BFleu2010117"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.117","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,3]]},"assertion":[{"value":"14 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}